comparemela.com

Latest Breaking News On - Liver fibrosis - Page 10 : comparemela.com

Can-Fite Reports 2022 Financial Results & Provides Clinical Update

PETACH TIKVA, Israel (BUSINESS WIRE) Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory

United statesPnina fishmanMotti farbsteinFite biopharmaKiryat matalonSoroka medical centerTrademark office granted canExchange commissionClinical development highlightsCompany annual report on formFite biopharma ltdEuropean medicines agencyDrug administrationCan fite biopharmaClinical development highlights includeTrial met primary endpoint

Screen High-Risk Individuals for NAFLD, Urges Guidance

Screening of high-risk individuals could identify asymptomatic cases and enable early intervention to prevent complications, experts write.

United statesUniversity of chicagoJamile wakim flemingMarye rinellaFatty liver disease programDrug administrationUniversity of chicago medicineAmerican associationChicago medicineMedscape medicalCleveland clinicNonalcoholic fatty liver diseaseBiliary diseaseAllbladder diseaseMetabolic syndromeLiver disease

Exercise Training Reduces Liver Fat in Patients With NAFLD

Exercise training can improve histologic response and liver fibrosis in patients with NAFLD.

United statesJill kanaleyJonathan stineUniversity of missouriNational institute of diabetesOngoing researchFatty liver programPenn state health miltonMedical centerMedscape medicalAmerican journalNational institutePublished januaryNonalcoholic fatty liver diseaseBiliary diseaseAllbladder disease

FIB-4 May Help Select Candidates for Heart Failure Tests

Heart failure and liver stiffness often coexist due to cardio-hepatic interactions.

Arita choChisato okamotoHeart failure associationNational cerebralCardiovascular centerOsaka university graduate school of medicineGastro hepOsaka university graduate schoolHeart failureBiliary diseaseAllbladder diseaseNonalcoholic fatty liver diseaseLiver diseaseMetabolic syndromeCardiovascular imagingArdiac imaging

Factors in liver fibrosis in patients with type 2 diabetes

For T2DM patients combined with NAFLD, older age, higher SBP, higher ALT, higher GGT, lower LDL, and lower PLT were relevant factors for LF.

World health organizationDepartment of endocrinologyHebei general hospitalClinical parameters between patientsClinical parametersDifferent degreesCorrelation analysisRegression analysisLiver fibrosisMellitus patients combinedNon alcoholic fatty liver

vimarsana © 2020. All Rights Reserved.